F

our years ago, ImmunoGen (IMGN) marked a significant achievement in the Waltham, Mass., company’s history with the market debut of Kadcyla, a breast cancer drug that uses innovative biotechnology to target cancer while sparing healthy cells.

The Genentech division of Swiss drug giant Roche won approval from U.S. and European regulators to sell Kadcyla, but the “payload platform” that enables the drug to bind to tumors was painstakingly developed over three decades by ImmunoGen.

Unlock this article by subscribing to STAT Plus today. Try it FREE for 30 days and cancel anytime!

SUBSCRIBE TODAY

What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Morning Rounds newsletter

Your daily dose of what’s new in health and medicine.